“If lower prices would diminish R&amp;D, why don't costly dividends? Why don't stock buybacks?”

“What could justify arbitrary prices increases year after year, long after the R&amp;D spending is done?”

—@RonWyden on drug companies’ excuses for high costs of prescription drugs https://t.co/ZZYiZMztJv
